CX 2024 Programme

Showing the latest CX 2024 Programme, talks, speakers and timings subject to change.
The organisers reserve the right to alter the programme as necessary.
All times are London time BST (British Summer Time), which is GMT+1. The organisers reserve the right to alter the timings if necessary.

Day 1: Peripheral Arterial Controversies - Tuesday, 23rd April
Venue:   Theatre 1
Time: 08:00 - 18:00
Paclitaxel Mortality Controversy
Time: 08:00 - 08:45
Anchor:   Andrew Holden, Auckland, New Zealand
Moderators:   Sahil Parikh, New York, United States
Marianne Brodmann, Graz, Austria
Barry Katzen, Miami, United States
08:00 - 08:05
Audience participation, discussion & voting
08:05 - 08:10
Update on the safety of paclitaxel-coated balloons for femoropopliteal occlusive disease
Speaker:   Thomas Zeller, Bad Krozingen, Germany
08:10 - 08:15
Paclitaxel and mortality
Speaker:   Peter Schneider, San Francisco, United States
08:15 - 08:20
Late Breaker: Did the meta-analysis and regulatory body restrictions on paclitaxel cause harm
Speaker:   Eric Secemsky, Boston, United States
Final Perspective from Regulatory Authorities
Time: 08:20 - 08:30
08:20 - 08:25
FDA response
Speaker:   Misti Malone, Silver Spring, United States
08:25 - 08:30
MHRA response
Speaker:   Alexander McLaren, London, United Kingdom
08:30 - 08:45
Audience participation, discussion & voting
Faculty:   Sahil Parikh, New York, United States
William Gray, Wynnewood, United States
Ariel Ash-Shakoor, Washingston, United States
 
Drug-Coated Balloons in the Femoropopliteal Arteries
Time: 08:45 - 10:10
Anchor:   Thomas Zeller, Bad Krozingen, Germany
Moderators:   Robert Hinchliffe, Bristol, United Kingdom
Robert Morgan, London, United Kingdom
08:45 - 08:50
Audience participation, discussion & voting
08:50 - 08:55
Paclitaxel and sirolimus-coated balloons in the femoropopliteal arteries: Mechanisms of action
Speaker:   Bruno Scheller, Hamburg, Germany
08:55 - 09:00
Long-term success with a market leading paclitaxel DCB: The IN.PACT RCT and Global Registry
Speaker:   Gunnar Tepe, Rosenheim, Germany
09:00 - 09:05
Three-year outcomes after paclitaxel-coated balloon angioplasty of femoropopliteal arteries among patients in the French National Health Data System
Speaker:   Yann Goueffic, Paris, France
09:05 - 09:20
Audience participation & discussion
09:20 - 09:25
Sirolimus trials in the SFA: SFA IDE and SUCCESS PTA trials
Speaker:   Michael Lichtenberg, Arnsberg, Germany
09:25 - 09:30
Sirolimus trials in the SFA, including the FUTURE SFA Asia RCT
Speaker:   Edward Choke, Bukit Merah, Singapore
09:30 - 09:35
Sirolimus vs paclitaxel, a head to head trial: Update of the SIRONA RCT
Speaker:   Ulf Teichgraeber, Jena, Germany
09:35 - 09:50
Audience participation & discussion
09:50 - 10:00
Debate: After the FDA announcement, paclitaxel-coated devices now beat limus-coated devices

For the motion
09:50 - 09:55
Andrew Holden, Auckland, New Zealand

Against the motion
09:55 - 10:00
Marianne Brodmann, Graz, Austria

10:00 - 10:10
Audience participation, discussion & voting
 
Coffee break
Time: 10:10 - 10:30
Bioresorbable Scaffolds in Tibial Arteries
Time: 10:30 - 11:20
Anchor:   Gunnar Tepe, Rosenheim, Germany
Moderators:   Sahil Parikh, New York, United States
Jos van den Berg, Lugano, Switzerland
10:30 - 10:35
Bioresorbable scaffolds in tibial arteries: The holy grail
Speaker:   Ramon Varcoe, Sydney, Australia
10:35 - 10:40
Late Breaker: Latest data release from the LIFE-BTK clinical trial
Speaker:   Brian DeRubertis, New York, United States
10:40 - 10:45
Current expectations of a CLTI clinical trial: A regulatory body perspective
Speaker:   Misti Malone, Silver Spring, United States
10:45 - 10:55
Audience participation & discussion
10:55 - 11:00
Update on a sirolimus-eluting PLLA scaffold in tibial arteries
Speaker:   Eric Secemsky, Boston, United States
11:00 - 11:05
Update on a bioresorbable scaffold in tibial arteries
Speaker:   Michel Bosiers, Bern, Switzerland
11:05 - 11:10
The multi-element balloon expandable bioresorbable vascular scaffold system in the SFA
Speaker:   Andrew Holden, Auckland, New Zealand
11:10 - 11:20
Audience participation & discussion
 
Vessel Preparation in Tibial Artery Occlusive Disease
Time: 11:20 - 12:30
Anchor:   Brian DeRubertis, New York, United States
Moderators:   Gunnar Tepe, Rosenheim, Germany
Lindsay Machan, Vancouver, Canada
11:20 - 11:25
What are the concepts behind vessel preparation devices?
Speaker:   Brian DeRubertis, New York, United States
11:25 - 11:30
What is the evidence for vessel preparation with atherectomy in BTK arteries?
Speaker:   Thomas Zeller, Bad Krozingen, Germany
11:30 - 11:35
Clinical outcomes for below-the-ankle intervention in CLI: A Liberty 360 study sub-analysis
Speaker:   George Adams, Chapel Hill, United States
11:35 - 11:45
Audience participation & discussion
11:45 - 11:50
Intravascular lithotripsy in BTK arteries: Data and new technologies
Speaker:   Andrew Holden, Auckland, New Zealand
11:50 - 11:55
Edited Case: Treatment of tibial lesions with a new laser-based IVL technology
Speaker:   Marianne Brodmann, Graz, Austria
11:55 - 12:05
Audience participation & discussion
12:05 - 12:10
An update on the DEEPER trials with a novel retrievable temporary stent system
Speaker:   Marianne Brodmann, Graz, Austria
12:10 - 12:15
CHOCO-CABANA trial: A prospective, randomised trial comparing a specialty balloon system versus conventional PTA in BTK arteries
Speaker:   Gunnar Tepe, Rosenheim, Germany
12:15 - 12:20
Are vessel preparation devices cost-effective?
Speaker:   Jos van den Berg, Lugano, Switzerland
12:20 - 12:30
Audience participation & discussion
 
Sponsored education
Time: 12:30 - 13:00
Advancements in lower limb PAD revascularisation: Role and value of sirolimus-eluting balloons
Time: 12:30 - 13:00
Moderator:   George Adams, Chapel Hill, United States
Faculty:   Athanasios Diamantopoulos, London, United Kingdom
Bruno Migliara, Peschiera del Garda, Italy
 
Lunch break
Time: 13:00 - 13:30
Inaugural Roger M Greenhalgh Late Breaking Trials Session
Time: 13:30 - 15:20
Deep Venous Arterialisation
Time: 13:30 - 14:35
Anchor:   Robert Hinchliffe, Bristol, United Kingdom
Moderators:   Thomas Zeller, Bad Krozingen, Germany
Andrew Holden, Auckland, New Zealand
13:30 - 13:35
Audience participation, discussion & voting
13:35 - 13:40
Transcatheter arterialisation of the deep veins: Highlights of the PROMISE trials
Speaker:   Daniel Clair, Nashville, United States
13:40 - 13:45
Late Breaker: New data from the CLARITY trial
Speaker:   Anahita Dua, Boston, United States
13:45 - 13:50
Late Breaker: Final results from the PROMISE UK trial
Speaker:   Hany Zayed, London, United Kingdom
13:50 - 14:00
Audience participation & discussion
14:00 - 14:05
The PiPeR DVA technique
Speaker:   Bruno Migliara, Peschiera del Garda, Italy
14:05 - 14:10
New considerations in DVA
Speaker:   Steven Kum, Singapore, Singapore
14:10 - 14:15
Post DVA management
Speaker:   Uei Pua, Singapore, Singapore
14:15 - 14:25
Audience participation & discussion
14:25 - 14:30
Deep venous arterialisation: A word of caution
Speaker:   Thomas Zeller, Bad Krozingen, Germany
14:30 - 14:35
Audience participation, discussion & voting
 
Aorto-iliac Occlusive Disease
Time: 14:35 - 15:20
Anchor:   Robert Morgan, London, United Kingdom
Moderators:   Brian DeRubertis, New York, United States
Thomas Zeller, Bad Krozingen, Germany
14:35 - 14:40
A new classification for aorto-iliac occlusive disease
Speaker:   Ross Milner, Chicago, United States
14:40 - 14:45
Results from the DISCOVER RCT
Speaker:   Bram Fioole, Rotterdam, Netherlands
14:45 - 14:50
An update of the FORWARD clinical study comparing uncovered to covered stents in the iliac arteries
Speaker:   Andrew Holden, Auckland, New Zealand
14:50 - 15:00
Audience participation & discussion
15:00 - 15:05
Expanding options to tackle iliac calcification with intravascular lithotripsy
Speaker:   Stefano Fazzini, Rome, Italy
15:05 - 15:10
Latest data on covered endovascular repair of the aortic bifurcation
Speaker:   Maria Antonella Ruffino, Lugano, Switzerland
15:10 - 15:20
Audience participation & discussion
 
Sponsored Education
Time: 15:20 - 15:50
Tea break
Time: 15:50 - 16:10
BASIL-3 Podium First Presentation
Time: 16:10 - 18:00
Anchor:   Andrew Holden, Auckland, New Zealand
Moderators:   Dittmar Boeckler, Heidelberg, Germany
Robert Hinchliffe, Bristol, United Kingdom
16:10 - 16:15
Introduction to BASIL-3
Speaker:   Andrew Bradbury, Birmingham, United Kingdom
16:15 - 16:20
Evidence for paclitaxel DCB/DES in CLTI before BASIL-3
Speaker:   Lewis Meecham, Cardiff, Wales
16:20 - 16:25
BASIL-3 in context: BASIL Prospective Cohort Study (PCS)
Speaker:   Matthew Popplewell, Birmingham, United Kingdom
16:25 - 16:30
BASIL-3 methodology: Clinical
Speaker:   Gareth Bate, Birmingham, United Kingdom
16:30 - 16:35
BASIL-3 methodology: Statistical
Speaker:   Jack Hall, Birmingham, United Kingdom
16:35 - 16:40
BASIL-3 clinical results
Speaker:   Catherine Moakes, Birmingham, United Kingdom
16:40 - 16:45
BASIL-3 health economic results
Speaker:   Jesse Kigozi, Birmingham, United Kingdom
16:45 - 16:50
Summing up, limitations, take home messages, and further research
Speaker:   Andrew Bradbury, Birmingham, United Kingdom
16:50 - 17:30
Audience participation & roundtable discussion
17:30 - 17:50
Great Debate: Bypass surgery is better than endovascular surgery

For the motion
17:30 - 17:35
Matthew Menard, Boston, United States

17:40 - 17:45
Michael Conte, San Francisco, United States

Against the motion
17:35 - 17:40
Andrew Bradbury, Birmingham, United Kingdom

17:45 - 17:50
Ramon Varcoe, Sydney, Australia

17:50 - 18:00
Audience participation, discussion & voting